Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Arian 22-23 Quiz

Total questions: 27

Worksheet time: 9mins

Name
Class
Date
1.

Istavel is a trusted real world companion to live well with diabetes across which patient groups

a)

Patients with Different baseline HbA1c

b)

Patients With different background therapies

c)

Diabetes patients with CV risk

d)

All of the above

2.

Merit HF trial enrolled patients with NYHA class

a)

I-II

b)

II-III

c)

II-IV

d)

Only IV

3.

Landmark trial for Ramipril with number of patients

a)

COMMIT, 5647

b)

RAMY, 8197

c)

HOPE, 9297

d)

HOPE, 9397

4.

Rivaflo 15/20 mg is effective in high risk population such as 

a)

Elderly patients

b)

Patients with Heart failure, diabetes

c)

History of stroke/TIA,prior MI and PAD

d)

All of the above

5.

Why is solusorb technology a USP for Tigatel

a)

Improved Bioavailability

b)

Reduced Inter-intra subject variability

c)

Rapid Dissolution

d)

All of the above

6.

Ketoanalogue delays the progression of CKD by

a)

Delaying Dialysis Initiation

b)

Delaying GFR Decline

c)

Reducing Serum Creatinine level

d)

All of the above

7.

Istavel offers _______ % & _______ % greater HbA1c reduction compared to Linagliptin & Vildagliptin respectively

a)

47% & 20%

b)

50% & 25%

c)

42% & 18%

d)

60% & 30%

8.

No. of patients in MERIT HF Trial

a)

2991

b)

3991

c)

4991

d)

5991

9.

Outcome of Tecos Trial- No increased CV risk including

a)

1. Heart attach

2. Non Fatal Stroke

3. Ischemia

4. Unstable Angina requiring Hospitalization

b)

1. CV Death

2. Non Fatal Stroke

3. Non Fatal MI

4. Unstable Angina requiring Hospitalization

c)

1. Arrhythmia

2. Fatal Stroke

3. Ischemia

4. Unstable Angina requiring Hospitalization

d)

1. Tachycardia

2. CAD

3. Atrial Fibrillation

4. Unstable Angina requiring Hospitalization

10.

What is the dose of Rivaflo In DVT/PE treatment

a)

Rivaroxaban 20 mg BID for 21 days

b)

Rivaroxaban 15 mg BID for 21 

c)

Rivaroxaban 15 mg BID for 21 days followed by 20 mg OD

d)

Rivaroxaban 10 mg BID

11.

What is the correct dosage of Ketoadd

a)

Thrice a day

b)

Twice a day

c)

1 tablet/5kg body weight

d)

1 tablet/10kg body weight

12.

What is the Indication for Tigatel CH & Targeted speciality

a)

In Hypertensive patients with Diabetes, Diabetologist

b)

In Hypertensive pts with CV risk, Cardiologists

c)

In Uncontrolled Hypertension, Cardiologist

d)

In Essential Hypertension, Cons. Physician

13.

TECOS trial included ____________patients with T2DM & established CVD

a)

15256

b)

14567

c)

14671

d)

14652

14.

Inability of Heart to pump enough blood to body is condition known as 

a)

MI

b)

Arrythmia

c)

Angina

d)

HF

15.

Telmisartan belongs to which class of drug

a)

CCB

b)

B Blocker

c)

ACEi

d)

ARB

16.

OD Dose of Sitagliptin offers ______ % of DPP4 Inhibition

a)

93%

b)

88

c)

90

d)

91.7

17.

Renal excretion of Rivaroxaban is

a)

35%

b)

30%

c)

25%

d)

10%

18.

What is the Indication for Tigatel AM & Targeted speciality

a)

In Hypertensive patients with Diabetes, Diabetologist& Physician

b)

In Hypertensive pts with CV risk, Cardiologists

c)

In Uncontrolled Hypertension, Nephrologists

d)

In Essential Hypertension, Cons. Physician

19.

How many patients experienced ICH in clinical trial and real world studies

a)

None of the patients

b)

Less than 1 % 

c)

Less than 2%

d)

Less than 3%

20.

In how many countries WRAP Matrix Technology patent is approved

a)

10

b)

18

c)

21

d)

27

21.

Istavel , Trusted real world companion, does not increase the risk of 

a)

Hypoglycemia

b)

Weight Gain

c)

PAOD

d)

All of the above

22.

Beta 1 receptor on activation causes

a)

Decrease Heart Rate

b)

Decrease FOC

c)

Increase FOC

d)

Decrease CO

23.

What is the indication for Ketoadd

a)

In the management of CKD

b)

In the Management of Fatigue and weakness

c)

In the management of Protein Energy Malnutrition in CKD patients

d)

In the Management of Body weight 

24.

The relative risk reduction of Major cardiovascualar event as per COMPASS trial

a)

35%

b)

24%

c)

15%

d)

10%

25.

2019 ESC CCS guidelines recommends B Blockers &/ CCBs in patients with

a)

MI

b)

Hypertension with Symptomatic Angina

c)

HF

d)

Stroke

26.

Istavel offers strong HbA1c reduction as high as ______ in patients with high baseline HbA1c levels

a)

2%

b)

3%

c)

3.60%

d)

4.20%

27.

What is the Saving % with Ketoadd compared to Leading brand in Market

a)

20%

b)

45%

c)

10%

d)

30%